BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rigillo N, Meloni T, Torelli M, Schettini F. [Haptoglobin and orosomucoid in the blood in a case of congenital afibrinogenemia and in the family of the patient]. Boll Soc Ital Biol Sper. 1968;44:81-83. [PMID: 5651986 DOI: 10.1186/1471-2407-5-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Mercer-Smith AR, Buckley A, Valdivia A, Jiang W, Thang M, Bell N, Kumar RJ, Bomba HN, Woodell AS, Luo J, Floyd SR, Hingtgen SD. Next-generation Tumor-homing Induced Neural Stem Cells as an Adjuvant to Radiation for the Treatment of Metastatic Lung Cancer. Stem Cell Rev Rep 2022. [PMID: 35441348 DOI: 10.1007/s12015-022-10375-3] [Reference Citation Analysis]
2 Tuomela K, Ambrose AR, Davis DM. Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity. Front Immunol 2022;13:867098. [PMID: 35401556 DOI: 10.3389/fimmu.2022.867098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
3 Tuomela K, Mukherjee D, Ambrose AR, Harikrishnan A, Mole H, Hurlstone A, Önfelt B, Honeychurch J, Davis DM. Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity. Proc Natl Acad Sci U S A 2022;119:e2111900119. [PMID: 35042775 DOI: 10.1073/pnas.2111900119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Makowska A, Lelabi N, Nothbaum C, Shen L, Busson P, Tran TTB, Eble M, Kontny U. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells. Cells 2021;10:2458. [PMID: 34572108 DOI: 10.3390/cells10092458] [Reference Citation Analysis]
5 Mercer-Smith AR, Jiang W, Bago JR, Valdivia A, Thang M, Woodell AS, Montgomery SA, Sheets KT, Anders CK, Hingtgen SD. Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer. Mol Cancer Ther 2021;20:2291-301. [PMID: 34433662 DOI: 10.1158/1535-7163.MCT-21-0109] [Reference Citation Analysis]
6 Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D, Jabbour SK. Combining radiation therapy and immunotherapy for lung cancers: a narrative review. Shanghai Chest 2021;5:10. [PMID: 33521559 DOI: 10.21037/shc-20-66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen J, Liu X, Zeng Z, Li J, Luo Y, Sun W, Gong Y, Zhang J, Wu Q, Xie C. Immunomodulation of NK Cells by Ionizing Radiation. Front Oncol 2020;10:874. [PMID: 32612950 DOI: 10.3389/fonc.2020.00874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
8 Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers (Basel) 2019;11:E1087. [PMID: 31370269 DOI: 10.3390/cancers11081087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
9 Lee MW, Kim DS, Kim HR, Park HJ, Lee JW, Sung KW, Koo HH, Yoo KH. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL. Cell Prolif 2019;52:e12577. [PMID: 30724400 DOI: 10.1111/cpr.12577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang SJ, Haffty B. Radiotherapy as a New Player in Immuno-Oncology. Cancers (Basel). 2018;10. [PMID: 30558196 DOI: 10.3390/cancers10120515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
11 Gillissen B, Richter A, Richter A, Preissner R, Schulze-Osthoff K, Essmann F, Daniel PT. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. J Biol Chem 2017;292:6478-92. [PMID: 28154184 DOI: 10.1074/jbc.M116.754184] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
12 Abou-Shousha S, Moaaz M, Sheta M, Motawea MA. An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti-Interleukin-6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma. Scand J Immunol 2016;83:427-37. [PMID: 26971879 DOI: 10.1111/sji.12426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Abraha AM, Ketema EB. Apoptotic pathways as a therapeutic target for colorectal cancer treatment. World J Gastrointest Oncol 2016; 8(8): 583-591 [PMID: 27574550 DOI: 10.4251/wjgo.v8.i8.583] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
14 Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol 2016;12:239-56. [PMID: 26621553 DOI: 10.2217/fon.15.300] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
15 Alexiou GA, Tsamis KI, Vartholomatos E, Peponi E, Tzima E, Tasiou I, Lykoudis E, Tsekeris P, Kyritsis AP. Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells. J Neurooncol 2015;123:217-24. [PMID: 25935110 DOI: 10.1007/s11060-015-1799-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
16 Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP. Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest 2013;31:630-8. [PMID: 24164301 DOI: 10.3109/07357907.2013.849724] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Acuña UM, Matthew S, Pan L, Kinghorn AD, Swanson SM, de Blanco EJ. Apoptosis induction by 13-acetoxyrolandrolide through the mitochondrial intrinsic pathway. Phytother Res 2014;28:1045-53. [PMID: 24338805 DOI: 10.1002/ptr.5091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
18 Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, Tobias AL, Mustafi D, Rincón E, Zhang L, Aboody KS, Lesniak MS. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014;22:140-8. [PMID: 24002694 DOI: 10.1038/mt.2013.199] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
19 Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther 2013;14:1016-23. [PMID: 24025362 DOI: 10.4161/cbt.26043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
20 Pan LQ, Wang HB, Lai J, Xu YC, Zhang C, Chen SQ. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials 2013;34:9115-23. [PMID: 23981355 DOI: 10.1016/j.biomaterials.2013.08.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
21 Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013;4:e688. [PMID: 23788045 DOI: 10.1038/cddis.2013.207] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
22 Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis 2013;4:e643. [PMID: 23703388 DOI: 10.1038/cddis.2013.67] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
23 Inoue T, Anai S, Onishi S, Miyake M, Tanaka N, Hirayama A, Fujimoto K, Hirao Y. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol 2013;13:1. [PMID: 23289871 DOI: 10.1186/1471-2490-13-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
24 Zhang L, Zhou F, Li Y, Drabsch Y, Zhang J, van Dam H, ten Dijke P. Fas-associated factor 1 is a scaffold protein that promotes β-transducin repeat-containing protein (β-TrCP)-mediated β-catenin ubiquitination and degradation. J Biol Chem 2012;287:30701-10. [PMID: 22730322 DOI: 10.1074/jbc.M112.353524] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
25 Kim HR, Lee MW, Kim DS, Jo HY, Lee SH, Chueh HW, Jung HL, Yoo KH, Sung KW, Koo HH. Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL. Cell Biol Int Rep (2010) 2012;19:e00017. [PMID: 23124518 DOI: 10.1042/CBR20110008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Ifeadi V, Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One 2012;7:e31762. [PMID: 22389673 DOI: 10.1371/journal.pone.0031762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
27 Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, Kim JH, Song MJ, Hong JT. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol 2012;258:72-81. [PMID: 22027265 DOI: 10.1016/j.taap.2011.10.009] [Cited by in Crossref: 136] [Cited by in F6Publishing: 131] [Article Influence: 12.4] [Reference Citation Analysis]
28 Niemoeller OM, Belka C. Radiotherapy and TRAIL for cancer therapy. Cancer Lett 2013;332:184-93. [PMID: 21824725 DOI: 10.1016/j.canlet.2011.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
29 Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, Chang JW, Oh W, Jeun SS. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28:2217-28. [PMID: 20945331 DOI: 10.1002/stem.543] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 9.0] [Reference Citation Analysis]
30 von Haefen C, Wendt J, Semini G, Sifringer M, Belka C, Radetzki S, Reutter W, Daniel PT, Danker K. Synthetic glycosidated phospholipids induce apoptosis through activation of FADD, caspase-8 and the mitochondrial death pathway. Apoptosis 2011;16:636-51. [DOI: 10.1007/s10495-011-0592-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
31 Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-108. [PMID: 20819019 DOI: 10.1517/14728222.2010.519701] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 10.5] [Reference Citation Analysis]
32 Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011;11:431-49. [PMID: 21263219 DOI: 10.4161/cbt.11.5.14671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
33 Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, Zhao QL, Ahmed K, Yasuda T, Seki S, Suzuki K, Kimura T. Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. J Orthop Res 2010;28:739-45. [PMID: 20041491 DOI: 10.1002/jor.21056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
34 Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, Gebhardt N, Preissner R, Belka C, Dörken B, Daniel PT. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010;188:851-62. [PMID: 20308427 DOI: 10.1083/jcb.200912070] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
35 Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resistance Updates 2010;13:29-43. [DOI: 10.1016/j.drup.2010.01.002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
36 Marini P, Junginger D, Stickl S, Budach W, Niyazi M, Belka C. Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Radiat Oncol 2009;4:49. [PMID: 19860913 DOI: 10.1186/1748-717X-4-49] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
37 Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 2009;625:63-72. [PMID: 19836385 DOI: 10.1016/j.ejphar.2009.06.066] [Cited by in Crossref: 130] [Cited by in F6Publishing: 128] [Article Influence: 10.0] [Reference Citation Analysis]
38 Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 2009;75:198-202. [PMID: 19695436 DOI: 10.1016/j.ijrobp.2009.04.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
39 Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade. Strahlenther Onkol 2009;185:8-18. [DOI: 10.1007/s00066-009-1856-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
40 Chometon G, Jendrossek V. Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy. Clin Transl Oncol 2009;11:75-81. [DOI: 10.1007/s12094-009-0317-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
41 Luce A, Courtin A, Levalois C, Altmeyer-Morel S, Romeo PH, Chevillard S, Lebeau J. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis 2009;30:432-9. [PMID: 19126655 DOI: 10.1093/carcin/bgp008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
42 Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-8. [PMID: 19117685 DOI: 10.1016/j.ctrv.2008.11.006] [Cited by in Crossref: 196] [Cited by in F6Publishing: 181] [Article Influence: 14.0] [Reference Citation Analysis]
43 Gürleyen H, Christiansen H, Tello K, Dudas J, Hermann RM, Rave-Fränk M, Hess CF, Ramadori G, Saile B. Irradiation leads to sensitization of hepatocytes to TNF-alpha-mediated apoptosis by upregulation of IkappaB expression. Radiat Environ Biophys 2009;48:85-94. [PMID: 18956207 DOI: 10.1007/s00411-008-0200-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol 2008;36:1660-72. [PMID: 18838202 DOI: 10.1016/j.exphem.2008.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
45 Maduro JH, de Vries EG, Meersma G, Hougardy BM, van der Zee AG, de Jong S. Targeting Pro-Apoptotic TRAIL Receptors Sensitizes HeLa Cervical Cancer Cells to Irradiation-Induced Apoptosis. International Journal of Radiation Oncology*Biology*Physics 2008;72:543-52. [DOI: 10.1016/j.ijrobp.2008.06.1902] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
46 Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630. [PMID: 18640940 DOI: 10.1200/jco.2007.15.7198] [Cited by in Crossref: 311] [Cited by in F6Publishing: 282] [Article Influence: 22.2] [Reference Citation Analysis]
47 Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90. [PMID: 18523647 DOI: 10.1172/JCI34359] [Cited by in Crossref: 236] [Cited by in F6Publishing: 224] [Article Influence: 16.9] [Reference Citation Analysis]
48 Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkötter U. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg 2007;20:339-48. [PMID: 18097875 DOI: 10.1080/08941930701772157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
49 Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production. Exp Cell Res 2008;314:1605-16. [PMID: 18313665 DOI: 10.1016/j.yexcr.2007.12.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
50 Mérino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007;11:1299-314. [PMID: 17907960 DOI: 10.1517/14728222.11.10.1299] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 7.9] [Reference Citation Analysis]
51 Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, Borst J. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008;27:574-84. [PMID: 17684487 DOI: 10.1038/sj.onc.1210696] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
52 Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, Zacharias W. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007;7:108. [PMID: 17592646 DOI: 10.1186/1471-2407-7-108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
53 Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 2007;12:1533-41. [DOI: 10.1007/s10495-007-0081-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
54 Pajak B, Orzechowski A. Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line. Anti-Cancer Drugs 2007;18:55-63. [DOI: 10.1097/cad.0b013e32800fee9e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
55 Wissink EH, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, Borst J, Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol 2006;80:214-22. [PMID: 16916556 DOI: 10.1016/j.radonc.2006.07.030] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
56 Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006;84:87-98. [PMID: 16405656 DOI: 10.1111/j.1440-1711.2005.01413.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
57 Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene. 2006;25:5145-5154. [PMID: 16636678 DOI: 10.1038/sj.onc.1209516] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
58 Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 2006;1:9. [PMID: 16722607 DOI: 10.1186/1748-717X-1-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
59 Rübel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol. 2006;1:6. [PMID: 16722524 DOI: 10.1186/1748-717x-1-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
60 Habermehl D, Kammerer B, Handrick R, Eldh T, Gruber C, Cordes N, Daniel PT, Plasswilm L, Bamberg M, Belka C, Jendrossek V. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 2006;6:14. [PMID: 16417634 DOI: 10.1186/1471-2407-6-14] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]